Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond

被引:111
作者
Colbert, Robert A. [1 ]
机构
[1] NIAMSD, NIH, Bethesda, MD 20892 USA
关键词
ONSET ANKYLOSING-SPONDYLITIS; GENOME-WIDE ASSOCIATION; IDIOPATHIC ARTHRITIS; PSORIATIC-ARTHRITIS; CHILDHOOD ARTHRITIS; RHEUMATOLOGY CLASSIFICATION; SERONEGATIVE ENTHESOPATHY; RADIOGRAPHIC PROGRESSION; INTERNATIONAL LEAGUE; DURBAN CRITERIA;
D O I
10.1038/nrrheum.2010.103
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Spondyloarthritis (SpA) refers to a spectrum of immune-mediated inflammatory diseases with overlapping features, which differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis and outcome. SpA frequently involves the axial skeleton, and can result in abnormal bone formation with eventual ankylosis of the spine, resulting in substantial disability. SpA often begins as an 'undifferentiated' disease, the presentation of which differs in children and adults; most notably, spinal involvement is uncommon, while hip arthritis and enthesitis are frequently seen in juvenile-onset disease. Currently, the classification of SpA in adults and children is approached differently. Using the International League of Associations for Rheumatology (ILAR) system for juvenile idiopathic arthritis, most childhood SpA is classified as enthesitis-related arthritis. However, in contrast to adult SpA classification, the presence of, or a family history of, psoriasis dictates a separate category of juvenile idiopathic arthritis. More importantly, the ILAR system does not specifically recognize the presence of axial disease in juvenile SpA. Resolution of these issues will improve communication and the transitioning of patients from pediatric to adult clinics, will facilitate research in genetics and pathogenesis, and will be particularly important in the evaluation of tumor necrosis factor inhibitors and other biologic agents for early, axial SpA.
引用
收藏
页码:477 / 485
页数:9
相关论文
共 70 条
[1]
AMOR B, 1990, REV RHUM, V57, P85
[2]
Comparison of Patients with Juvenile Psoriatic Arthritis and Nonpsoriatic Juvenile Idiopathic Arthritis: How Different Are They? [J].
Aviel, Yonatan Butbul ;
Tyrrell, Pascal N. ;
Schneider, Rayfel ;
Dhillon, Sandeep ;
Feldman, Brian M. ;
Laxer, Ronald M. ;
Saurenmann, Rotraud K. ;
Spiegel, Lynn ;
Cameron, Bonnie ;
Tse, Shirley M. ;
Silverman, Earl D. .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (09) :2033-2041
[3]
Berntson L, 2008, J RHEUMATOL, V35, P2055
[4]
TH-17 cells in the circle of immunity and autoimmunity [J].
Bettelli, Estelle ;
Oukka, Mohamed ;
Kuchroo, Vijay K. .
NATURE IMMUNOLOGY, 2007, 8 (04) :345-350
[5]
Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis [J].
Brown, MA ;
Laval, SH ;
Brophy, S ;
Calin, A .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (11) :883-886
[6]
Genetics and the pathogenesis of ankylosing spondylitis [J].
Brown, Matthew A. .
CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (04) :318-323
[7]
Burgos-Vargas R, 2002, J RHEUMATOL, V29, P869
[8]
A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies [J].
Burgos-Vargas, R ;
Vázquez-Mellado, J ;
Pacheco-Tena, C ;
Hernández-Garduño, A ;
Goycochea-Robles, MV .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) :941-942
[9]
Juvenile-onset spondyloarthropathies [J].
BurgosVargas, R ;
PachecoTena, C ;
VazquezMellado, J .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1997, 23 (03) :569-+
[10]
CABRAL DA, 1992, J RHEUMATOL, V19, P1282